Listener feedback, CRT vs CSP, important clues on the ECG, beta-blocker interruption after myocardial infarction, novel approaches to LDL-C lowering, and ICD decisions in cardiac sarcoidosis are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

II CRT vs CSP – CONSYST-CRT

• Trial JACC EP https://doi.org/10.1016/j.jacep.2025.03.024

III The Important QRS

• Kewcharoen et al https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013809

IV ABYSS Trial of BB Interruption after MI Continues to be Mis-interpreted

• ABYSS Main https://www.nejm.org/doi/full/10.1056/NEJMoa2404204

• ABYSS substudy https://doi.org/10.1093/eurheartj/ehaf170

• REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479

V Oral PCSK9i and the PURSUIT Trial

• Koren et al https://www.jacc.org/doi/10.1016/j.jacc.2025.03.499

• Editorial https://doi.org/10.1016/j.jacc.2025.03.518

• Is Lifelong LDL-C Lowering Within Reach? The heart-1 Gene-Editing Trial https://www.medscape.com/viewarticle/998162

• Heart-1 Gene Therapy Trial Pauses Enrollment https://www.medscape.com/viewarticle/998162

• EHJ coverage VERVE https://academic.oup.com/ehjcvp/article/10/2/87/7455877

VI Cardiac Sarcoidosis and Risk of VT

• EHJ paper Mathijssen et al https://doi.org/10.1093/eurheartj/ehaf338

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Listener feedback on sports “disqualification,” big digoxin news, Brugada syndrome, another positive finerenone study, and unblinded transcatheter trials are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

• JACC EP Paper https://www.jacc.org/doi/10.1016/j.jacep.2025.03.013

II Digoxin News

• DIGIT HF Baseline Characteristics paper https://doi.org/10.1002/ejhf.3679
• DIGIT HF Rationale paper https://pmc.ncbi.nlm.nih.gov/articles/PMC6607489/
• Dig trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801
• DECISION trial https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.3428
• Ziff et al BMJ meta-analysis https://www.bmj.com/content/351/bmj.h4451

III Brugada Syndrome

• Gomes et al https://doi.org/10.1093/europace/euaf091

IV Another Finerenone Substudy Published

• FINEARTS-HF trial substudy, Bhatt, A et al https://doi.org/10.1016/j.cardfail.2025.05.006
• FINEARTS HF Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
• TOPCAT https://www.nejm.org/doi/full/10.1056/NEJMoa1313731
• TOPCAT regional variation Circ paper https://www.ahajournals.org/doi/10.1161/circulationaha.114.013255

V Another Opinion on Unblinded Transcatheter Intervention Trials

• Kaul https://eurointervention.pcronline.com/article/unblinded-trials-of-transcatheter-interventions-with-subjective-endpoints-what-are-the-implications

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

The BedMed trial of nighttime BP meds, SURMOUNT-5, Troponin URL, gene tests in patients with no disease, and guideline-directed medical therapy for HF are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Timing of BP Meds – The BedMed RCT

• MAPEC https://doi.org/10.3109/07420528.2010.510230
• Hygia https://doi.org/10.1093/eurheartj/ehz754
• Turgeon et al https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.16501
• TIME trial https://doi.org/10.1016/S0140-6736(22)01786-X
• BedMed https://jamanetwork.com/journals/jama/fullarticle/2833860
• Time Antihypertensives Taken Doesn't Matter: New Trials https://www.medscape.com/viewarticle/time-antihypertensives-taken-doesnt-matter-new-trials-2024a1000g3z
• Timing of BP Dosing Doesn't Matter: BedMed and BedMed-Frail https://www.medscape.com/viewarticle/timing-blood-pressure-dosing-doesnt-matter-again-bedmed-and-2024a1000fz2
• Timing of Blood Pressure Meds Doesn’t Affect Outcomes: BedMed in Print https://www.medscape.com/viewarticle/timing-blood-pressure-meds-doesnt-affect-outcomes-bedmed-2025a1000cdm

II Tirzepatide vs Semaglutide

• SURMOUNT 5 https://www.nejm.org/doi/full/10.1056/NEJMoa2416394

III Age-specific Troponins

• Coyle and McEvoy https://doi.org/10.1093/eurheartj/ehaf308
• Mandrola/Foy JAMA-IM https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967

IV Return to Play for Gene Positive Phenotype Negative athletes

• Martinez et al https://doi.org/10.1016/j.jacep.2025.03.013

V Rapid Titration of GDMT in HF

STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698

• JACC-HF Substudy https://doi.org/10.1016/j.jchf.2025.02.020
• STRONG HF https://doi.org/10.1016/S0140-6736(22)02076-1
• AVID https://www.nejm.org/doi/full/10.1056/NEJMoa013474
• EAST https://www.nejm.org/doi/full/10.1056/NEJMoa013474

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net